The one thing everyone seems to forget.....is that Bavi isn't competing with any one drug or class or drugs. It's there to make those drugs work better.
Big pharma shouldn't have anything to fear. They should embrace the technology now to be first. That's the smart play for them IMHO.
Biopharm I love your enthusiasm but in my opinion the end game is now in play. Not a bad thing for us longs but it is what it is. Frankly Peregrine can NOT get Bavituximab approval with out a big pharma. What is taking place today is a merger buyout by AZN IMO. They are buying shares hand over fist at these prices and will continue when we have some "real" volume days this week. The shaking of the tree is happening and most retail will be happy to sell as the stock gets back to a dollar most likely this week. AZN will own 30 percent of the company at roughly 1/share and will most likely do a deal to the tune of 100m down and 50/50 rights to Bavituximab. As the stock climbs to 4/share this summer we will most likely wake up to full buyout at 8-12/share. Don't worry about the board there will be plenty of caveats for them and senior management getting shares of AZN.
Market Data 
Markets 
AI
